[artículo] 
inJournal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 1 (Febrero) . - pp. 51-57

Título :	Anticipatory anxiety in moderately to highly-anxious oral surgery patients as a screening model for anxiolytics: evaluation of alprazolam
Tipo de documento:	texto impreso
Autores:	Daniel L. Wolf, Autor ; Paul J. Desjardins, Autor ; Peter M. Black, Autor
Fecha de publicación:	2023
Artículo en la página:	pp. 51-57
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Alprazolam, Ansiolíticos, Ansiedad, Presión arterial.
Resumen:	Alprazolam, a benzodiazepine anxiolytic, was evaluated in anxious patients prior to oral surgery. This population represents a possible acute screening model for novel anxiolytic agents. Healthy subjects, preselected for a moderate to high degree of dental anxiety based upon Corah’s Dental Anxiety Scale, were enrolled in a three-arm parallel design study and randomly assigned to receive double-blind placebo (N=15), alprazolam 0.25 mg (N=16) or alprazolam 1 mg (N=16). Subjective selfreported anxiety was rated using the State Anxiety Inventory and visual analog scales.
Link:	./index.php?lvl=notice_display&id=31045

[artículo] Anticipatory anxiety in moderately to highly-anxious oral surgery patients as a screening model for anxiolytics: evaluation of alprazolam [texto impreso] / Daniel L. Wolf, Autor ; Paul J. Desjardins, Autor ; Peter M. Black, Autor . - 2023 . - pp. 51-57.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 1 (Febrero) . - pp. 51-57

Palabras clave:	Alprazolam, Ansiolíticos, Ansiedad, Presión arterial.
Resumen:	Alprazolam, a benzodiazepine anxiolytic, was evaluated in anxious patients prior to oral surgery. This population represents a possible acute screening model for novel anxiolytic agents. Healthy subjects, preselected for a moderate to high degree of dental anxiety based upon Corah’s Dental Anxiety Scale, were enrolled in a three-arm parallel design study and randomly assigned to receive double-blind placebo (N=15), alprazolam 0.25 mg (N=16) or alprazolam 1 mg (N=16). Subjective selfreported anxiety was rated using the State Anxiety Inventory and visual analog scales.
Link:	./index.php?lvl=notice_display&id=31045